Research

Open to Enrollment

CTEP: 9204/DFCI 12-537: A Phase I/Ib Study of Ipilimumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (NCT 01822509)

Participating Sites:

• Blood and Marrow Transplant Group of Georgia at Northside Hospital (Atlanta, Georgia)
• Eastern Maine Medical Center (Bangor, Maine)

DF/HCC 14-296: A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia (NCT 02251548)

Participating Sites:

• Eastern Maine Medical Center (Bangor, Maine)

DF/HCC 14-396: A Multicenter Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies (NCT 02268851)

Participating Sites:

• Blood and Marrow Transplant Group of Georgia at Northside Hospital (Atlanta, Georgia)
• Eastern Maine Medical Center (Bangor, Maine)
• Kadlec Clinic Hematology Oncology (Kennewick, Washington)
• Pacific Cancer Care (Monterey Bay, California)
• St. Francis Cancer Center (Hartford, Connecticut)
• West Michigan Cancer Center (Kalamazoo, Michigan)

DF/HCC 14-338: Phase II Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma (NCT 02279394)

Participating Sites:

• Colorado Blood Cancer Institute (Denver, Colorado)
• Eastern Maine Medical Center (Bangor, Maine)
• Hematology/Oncology of Northern New Jersey (Morristown, New Jersey)
• St. Francis Cancer Center (Hartford, Connecticut)

DF/HCC 14-508: A Phase II study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma (NCT 02441686)

Participating Sites:

• Hematology/Oncology of Northern New Jersey (Morristown, New Jersey)
• Virginia Piper Cancer Center (Minneapolis, Minnesota)
• New York Oncology Hematology (New York State)
• Eastern Maine Medical Center (Bangor, Maine)

DF/HCC 14-174: A Prospective, Longitudinal, Observational Study in Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome

Participating Sites:

• Eastern Maine Medical Center (Bangor, Maine)
• West Michigan Cancer Center (Kalamazoo, Michigan)
• Northside Hospital and Cancer Institute (Atlanta, Georgia)